II
MRTX

Inspire Investing’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Inspire Investing’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,561
Closed -$385K – 886
2023
Q4 		$385K Sell
6,561
-436
-6% -$24.5K 0.04% 466
2023
Q3 		$305K Sell
6,997
-1,688
-19% -$60.3K 0.04% 755
2023
Q2 		$314K Buy
8,685
+1,334
+18% +$55K 0.04% 601
2023
Q1 		$273K Buy
7,351
+2,136
+41% +$96.1K 0.03% 566
2022
Q4 		$236K Buy
5,215
+2,254
+76% +$146K 0.03% 448
2022
Q3 		$207K Buy
+2,961
New +$219K 0.03% 576

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Inspire Investing's MRTX Position: Q1 2024 in Review

Inspire Investing sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 6,561 shares — an estimated $385K sold.

Inspire Investing first reported a position in MRTX in Q3 2022 and held it in 6 quarters. The position peaked at $385K in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Inspire Investing reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Inspire Investing sold 6,561 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $385K.
  • Inspire Investing first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2022 and held it in 6 quarters.
  • Inspire Investing's Mirati Therapeutics, Inc. Common Stock position peaked at $385K in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Inspire Investing's 13F filing for Q1 2024, filed 7 May 2024.